Actively Recruiting
Multinational Phase 3 Trial Evaluating Pemvidutide Versus Placebo in Adults With Noncirrhotic Metabolic Dysfunction-Associated Steatohepatitis
Led by Altimmune, Inc. · Updated on 2026-09-23
1800
Participants Needed
9
Research Sites
208 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting a Phase 3, multinational, randomized, double-blind, placebo-controlled study to evaluate the effects of pemvidutide in adults with noncirrhotic metabolic dysfunction-associated steatohepatitis MASH classified as F2 or F3 fibrosis. The study includes two groups one identified by liver biopsy and the other by non-invasive tests, aiming to assess the drugs efficacy, safety, and clinical outcomes. Participants will be randomly assigned to receive either pemvidutide at doses of 1.8 mg or 2.4 mg, or a placebo, administered as subcutaneous injections. The trial follows a parallel-group design and will monitor responses over time, including liver histology and clinical events, with a treatment period extending through Week 52 and follow-up continuing up to approximately 60 months. Throughout the study, participants will undergo liver biopsies as required, along with assessments of liver function, fibrosis, metabolic parameters, body measurements, and quality of life using specific questionnaires. Researchers will track clinical outcome events and histological changes to evaluate the drugs impact while monitoring safety and tolerability. The total participation duration may extend up to around five years.
CONDITIONS
Brief Title
Phase 3 Study of the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in MASH
Research Team
S
Shaheen Tomah, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here